Judit Boda-Heggemann1, Anika Jahnke2, Mark K H Chan3, Leila S Ghaderi Ardekani3, Peter Hunold4, Jost Philipp Schäfer5, Stefan Huttenlocher6, Stefan Wurster6,7, Dirk Rades8, Guido Hildebrandt9, Frank Lohr10, Jürgen Dunst3,11, Frederik Wenz2, Oliver Blanck3,6. 1. Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer Ufer 1-3, 68167, Mannheim, Germany. judit.boda-heggemann@umm.de. 2. Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer Ufer 1-3, 68167, Mannheim, Germany. 3. Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany. 4. Department of Radiology and Nuclear Medicine, University Medical Center Schleswig-Holstein, Lübeck, Germany. 5. Department of Radiology and Neuroradiology, University Medical Center Schleswig-Holstein, Kiel, Germany. 6. Saphir Radiosurgery Center, Güstrow, Germany. 7. Department of Radiation Oncology, University Medicine Greifswald, Greifswald, Germany. 8. Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Lübeck, Germany. 9. Department of Radiation Oncology, University Medicine Rostock, Rostock, Germany. 10. UO di Radioterapia, Dipartimento di Oncologia, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy. 11. Department of Radiation Oncology, University Hospital Copenhagen, Copenhagen, Denmark.
Abstract
PURPOSE: For assessing healthy liver reactions after robotic SBRT (stereotactic body radiotherapy), we investigated early morphologic alterations on MRI (magnetic resonance imaging) with respect to patient and treatment plan parameters. PATIENTS AND METHODS: MRI data at 6-17 weeks post-treatment from 22 patients with 42 liver metastases were analyzed retrospectively. Median prescription dose was 40 Gy delivered in 3-5 fractions. T2- and T1-weighted MRI were registered to the treatment plan. Absolute doses were converted to EQD2 (Equivalent dose in 2Gy fractions) with α/β-ratios of 2 and 3 Gy for healthy, and 8 Gy for modelling pre-damaged liver tissue. RESULTS: Sharply defined, centroid-shaped morphologic alterations were observed outside the high-dose volume surrounding the GTV. On T2-w MRI, hyperintensity at EQD2 isodoses of 113.3 ± 66.1 Gy2, 97.5 ± 54.7 Gy3, and 66.5 ± 32.0 Gy8 significantly depended on PTV dimension (p = 0.02) and healthy liver EQD2 (p = 0.05). On T1-w non-contrast MRI, hypointensity at EQD2 isodoses of 113.3 ± 49.3 Gy2, 97.4 ± 41.0 Gy3, and 65.7 ± 24.2 Gy8 significantly depended on prior chemotherapy (p = 0.01) and total liver volume (p = 0.05). On T1-w gadolinium-contrast delayed MRI, hypointensity at EQD2 isodoses of 90.6 ± 42.5 Gy2, 79.3 ± 35.3 Gy3, and 56.6 ± 20.9 Gy8 significantly depended on total (p = 0.04) and healthy (p = 0.01) liver EQD2. CONCLUSIONS: Early post-treatment changes in healthy liver tissue after robotic SBRT could spatially be correlated to respective isodoses. Median nominal doses of 10.1-11.3 Gy per fraction (EQD2 79-97 Gy3) induce characteristic morphologic alterations surrounding the lesions, potentially allowing for dosimetric in-vivo accuracy assessments. Comparison to other techniques and investigations of the short- and long-term clinical impact require further research.
PURPOSE: For assessing healthy liver reactions after robotic SBRT (stereotactic body radiotherapy), we investigated early morphologic alterations on MRI (magnetic resonance imaging) with respect to patient and treatment plan parameters. PATIENTS AND METHODS: MRI data at 6-17 weeks post-treatment from 22 patients with 42 liver metastases were analyzed retrospectively. Median prescription dose was 40 Gy delivered in 3-5 fractions. T2- and T1-weighted MRI were registered to the treatment plan. Absolute doses were converted to EQD2 (Equivalent dose in 2Gy fractions) with α/β-ratios of 2 and 3 Gy for healthy, and 8 Gy for modelling pre-damaged liver tissue. RESULTS: Sharply defined, centroid-shaped morphologic alterations were observed outside the high-dose volume surrounding the GTV. On T2-w MRI, hyperintensity at EQD2 isodoses of 113.3 ± 66.1 Gy2, 97.5 ± 54.7 Gy3, and 66.5 ± 32.0 Gy8 significantly depended on PTV dimension (p = 0.02) and healthy liver EQD2 (p = 0.05). On T1-w non-contrast MRI, hypointensity at EQD2 isodoses of 113.3 ± 49.3 Gy2, 97.4 ± 41.0 Gy3, and 65.7 ± 24.2 Gy8 significantly depended on prior chemotherapy (p = 0.01) and total liver volume (p = 0.05). On T1-w gadolinium-contrast delayed MRI, hypointensity at EQD2 isodoses of 90.6 ± 42.5 Gy2, 79.3 ± 35.3 Gy3, and 56.6 ± 20.9 Gy8 significantly depended on total (p = 0.04) and healthy (p = 0.01) liver EQD2. CONCLUSIONS: Early post-treatment changes in healthy liver tissue after robotic SBRT could spatially be correlated to respective isodoses. Median nominal doses of 10.1-11.3 Gy per fraction (EQD2 79-97 Gy3) induce characteristic morphologic alterations surrounding the lesions, potentially allowing for dosimetric in-vivo accuracy assessments. Comparison to other techniques and investigations of the short- and long-term clinical impact require further research.
Entities:
Keywords:
CyberKnife; Liver metastases; MRI; Normal tissue reactions; SBRT
Authors: Simon S Lo; Bin S Teh; Jian Z Wang; Zhibin Huang; Jennifer Zook; Tracy Price; Nina A Mayr; John C Grecula; Robert D Timmerman; Higinia R Cardenes Journal: Expert Rev Anticancer Ther Date: 2011-04 Impact factor: 4.512
Authors: R J Klement; M Guckenberger; H Alheid; M Allgäuer; G Becker; O Blanck; J Boda-Heggemann; T Brunner; M Duma; S Gerum; D Habermehl; G Hildebrandt; V Lewitzki; C Ostheimer; A Papachristofilou; C Petersen; T Schneider; R Semrau; S Wachter; N Andratschke Journal: Radiother Oncol Date: 2017-03-06 Impact factor: 6.280
Authors: Florian Sterzing; Thomas B Brunner; Iris Ernst; Wolfgang W Baus; Burkhard Greve; Klaus Herfarth; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2014-08-05 Impact factor: 3.621
Authors: P Hoegen; K S Zhang; E Tonndorf-Martini; F Weykamp; S Regnery; P Naumann; K Lang; J Ristau; S A Körber; C Dreher; C Buchele; C Rippke; C K Renkamp; K M Paul; L König; C Büsch; J Krisam; O Sedlaczek; H-P Schlemmer; M Niyazi; S Corradini; J Debus; S Klüter; J Hörner-Rieber Journal: Radiat Oncol Date: 2022-03-27 Impact factor: 3.481